GlassScriptPhysician profile
Meredith L Harvie
NPI 1285020206
$3,128.42
in general payments reported to CMS, 2019-2025
26 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $493 · 2022: $859 · 2023: $676 · 2024: $831 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $683.72 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $473.03 | 2022-2025 | Dupixent |
| Genzyme Corporation | $445.54 | 2022-2025 | |
| Qol Medical, LLC | $255.44 | 2021-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $199.31 | 2021-2024 | Gattex, Eohilia |
| Janssen Biotech, INC. | $185.00 | 2021-2025 | Stelara, Simponi, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $166.81 | 2021-2023 | |
| Alcresta Therapeutics, INC. | $138.66 | 2022-2024 | Relizorb |
| Mirum Pharmaceuticals, INC. | $102.47 | 2022-2023 | Livmarli |
| Organon LLC | $48.37 | 2023-2024 | Renflexis, Hadlima |
| Gilead Sciences, INC. | $45.37 | 2022-2024 | |
| Rhythm Pharmaceuticals, INC. | $38.74 | 2024-2025 | Imcivree |
| Phadia US INC. | $36.97 | 2022-2025 | Immunocap |
| Albireo Pharma, INC. | $36.35 | 2022-2023 | Bylvay |
| Janssen Scientific Affairs, LLC | $35.63 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $35.00 | 2022 | |
| Sandoz INC. | $30.30 | 2023 | Hyrimoz |
| Madrigal Pharmaceuticals | $28.84 | 2024 | Resmetirom |
| Fresenius Kabi USA, LLC | $27.16 | 2023 | Idacio |
| Novo Nordisk INC | $18.76 | 2025 | Wegovy |
| Genentech USA, INC. | $18.14 | 2024 | Xolair |
| Pharming Healthcare, INC. | $16.59 | 2022 | |
| Echosens North America, INC. | $16.29 | 2024 | Fibroscan |
| Ipsen Biopharmaceuticals, INC | $16.14 | 2024 | Bylvay |
| Biogen, INC. | $15.41 | 2022 | |
| Endogastric Solutions, INC | $14.38 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Harvie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.